PMID- 33014054
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201006
IS  - 1687-8450 (Print)
IS  - 1687-8469 (Electronic)
IS  - 1687-8450 (Linking)
VI  - 2020
DP  - 2020
TI  - Clinical Significance of the Interleukin 24 mRNA Level in Head and Neck Squamous 
      Cell Carcinoma and Its Subgroups: An In Silico Investigation.
PG  - 7042025
LID - 10.1155/2020/7042025 [doi]
LID - 7042025
AB  - IL24 mRNA is known to have an apoptotic effect on cancer cells but not on 
      noncancer cells. However, the expression level of the IL24 mRNA in head and neck 
      squamous cell carcinoma (HNSCC) and its subgroups is rarely studied. In this 
      study, the clinical implication of IL24 mRNA was evaluated in the common 
      subgroups of HNSCC, including oral squamous cell carcinoma (OSCC), nasopharyngeal 
      carcinoma (NPC), and laryngeal squamous cell carcinoma (LSCC) for analysis. 
      Substantial IL24 mRNA expression data were calculated from several databases, 
      such as the Gene Expression Omnibus (GEO), ArrayExpress, Sequence Read Archive 
      (SRA), ONCOMINE, and The Cancer Genome Atlas (TCGA) databases. We ultimately 
      collected a total of 41 microarrays and RNA-seq including 1,564 HNSCC and 603 
      noncancer tissue samples. IL24 mRNA was highly expressed in OSCC, LSCC, and NPC 
      as shown by the separated standard mean difference (SMD), as well as HNSCC as a 
      whole part (SMD = 1.47, 95% confdence interval (CI) = 1.24-1.70, P < 0.0001). In 
      all subgroups, the IL24 mRNA upregulation had the ability to distinguish cancer 
      from noncancer tissue with area under the curves (AUCs) of the summary receiver 
      operating characteristic (sROC) higher than 0.85. In conclusion, IL24 mRNA may be 
      used as a potential marker for cancer screening, and its clinical diagnostic 
      value needs to be further studied. It also provides a new idea for the treatment 
      of the IL24 gene in HNSCC and its subgroups in the future.
CI  - Copyright (c) 2020 Lan-Lan Qiu et al.
FAU - Qiu, Lan-Lan
AU  - Qiu LL
AD  - Department of Cell Biology and Genetics, School of Pre-clinical Medicine, Guangxi 
      Medical University, Nanning 530021, Guangxi Zhuang Autonomous Region, China.
AD  - Department of Pathophysiology, School of Pre-clinical Medicine, Guangxi Medical 
      University, Nanning 530021, Guangxi Zhuang Autonomous Region, China.
FAU - Zhang, Xiao-Guohui
AU  - Zhang XG
AD  - Department of Cell Biology and Genetics, School of Pre-clinical Medicine, Guangxi 
      Medical University, Nanning 530021, Guangxi Zhuang Autonomous Region, China.
FAU - Chen, Gang
AU  - Chen G
AUID- ORCID: 0000-0003-2402-2987
AD  - Department of Pathology, First Affiliated Hospital, Guangxi Medical University, 
      Nanning 530021, Guangxi Zhuang Autonomous Region, China.
FAU - Dang, Yi-Wu
AU  - Dang YW
AD  - Department of Pathology, First Affiliated Hospital, Guangxi Medical University, 
      Nanning 530021, Guangxi Zhuang Autonomous Region, China.
FAU - Huang, Zhi-Guang
AU  - Huang ZG
AD  - Department of Pathology, First Affiliated Hospital, Guangxi Medical University, 
      Nanning 530021, Guangxi Zhuang Autonomous Region, China.
FAU - Li, Ming-Xuan
AU  - Li MX
AD  - Department of Pathology, First Affiliated Hospital, Guangxi Medical University, 
      Nanning 530021, Guangxi Zhuang Autonomous Region, China.
FAU - Liang, Yao
AU  - Liang Y
AD  - Department of Cell Biology and Genetics, School of Pre-clinical Medicine, Guangxi 
      Medical University, Nanning 530021, Guangxi Zhuang Autonomous Region, China.
FAU - Huang, Su-Ning
AU  - Huang SN
AD  - Department of Head and Neck Tumor Surgery, Guangxi Medical University Cancer 
      Hospital, Nanning 530021, Guangxi Zhuang Autonomous Region, China.
FAU - Tang, Xiao-Zhun
AU  - Tang XZ
AD  - Department of Radiotherapy, Guangxi Medical University Cancer Hospital, Nanning 
      530021, Guangxi Zhuang Autonomous Region, China.
FAU - Chen, Xiao-Xia
AU  - Chen XX
AD  - Department of Cell Biology and Genetics, School of Pre-clinical Medicine, Guangxi 
      Medical University, Nanning 530021, Guangxi Zhuang Autonomous Region, China.
FAU - Wei, Hong-Yu
AU  - Wei HY
AUID- ORCID: 0000-0001-8502-1254
AD  - Department of Organic Chemistry and Medicinal Chemistry, Pharmaceutical College, 
      Guangxi Medical University, Nanning 530021, Guangxi Zhuang Autonomous Region, 
      China.
FAU - Wu, Hua-Yu
AU  - Wu HY
AUID- ORCID: 0000-0002-6346-6292
AD  - Department of Cell Biology and Genetics, School of Pre-clinical Medicine, Guangxi 
      Medical University, Nanning 530021, Guangxi Zhuang Autonomous Region, China.
LA  - eng
PT  - Journal Article
DEP - 20200918
PL  - Egypt
TA  - J Oncol
JT  - Journal of oncology
JID - 101496537
PMC - PMC7519990
COIS- The authors declare that they have no conflicts of interest.
EDAT- 2020/10/06 06:00
MHDA- 2020/10/06 06:01
PMCR- 2020/09/18
CRDT- 2020/10/05 06:17
PHST- 2020/02/23 00:00 [received]
PHST- 2020/07/02 00:00 [accepted]
PHST- 2020/10/05 06:17 [entrez]
PHST- 2020/10/06 06:00 [pubmed]
PHST- 2020/10/06 06:01 [medline]
PHST- 2020/09/18 00:00 [pmc-release]
AID - 10.1155/2020/7042025 [doi]
PST - epublish
SO  - J Oncol. 2020 Sep 18;2020:7042025. doi: 10.1155/2020/7042025. eCollection 2020.